Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

Author's Avatar
Jan 22, 2020
Article's Main Image

SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing the following in response to inquires from multiple academic, government, investor, and media stakeholders.